Key Takeaways
- • Apax Partners acquires Gerresheimer's Primary Packaging Plastics division and US-based Centor for €1.5bn (enterprise value including debt), representing a significant carve-out of the German pharmaceutical packaging manufacturer's operations.
- • The divested businesses generated approximately €570m in revenue in the last financial year and operate 16 manufacturing facilities across nine countries plus the United States, employing around 2,400 people globally.
- • Gerresheimer will deploy proceeds to materially reduce leverage and strengthen its capital structure following a period of financial and governance disruption, including accounting review delays and regulatory audits by Germany's BaFin.
- • The transaction forms part of Gerresheimer's broader strategic review announced earlier in 2026, positioning the company to reinforce its financial position after removal from Deutsche Boerse's SDAX small-cap index due to reporting delays.
Summary
Apax Partners has agreed to acquire two plastic packaging divisions from Gerresheimer in a €1.5bn transaction that underscores both the German manufacturer's deleveraging priorities and the private equity firm's expansion in the pharmaceutical packaging sector. The deal encompasses Gerresheimer's global Primary Packaging Plastics division and Centor, a US-based pharmaceutical packaging manufacturer, representing a strategic exit for Gerresheimer as it navigates a period of financial and operational reassessment.
The combined businesses delivered approximately €570m in annual revenue and operate a substantial manufacturing footprint, including 15 facilities under Primary Packaging Plastics across nine countries and Centor's US production site. The workforce across both operations totals approximately 2,400 employees. By consolidating these assets under Apax management, the transaction creates a focused player in pharmaceutical plastic packaging while enabling Gerresheimer to address its pressing balance sheet concerns.
Gerresheimer's decision to divest these operations reflects the company's efforts to recover from a challenging period marked by accounting irregularities and regulatory scrutiny. The company's financial reporting was delayed following an internal review of accounting practices, resulting in its removal from Deutsche Boerse's SDAX index and triggering audits by Germany's financial regulator, BaFin. While Gerresheimer concluded its internal accounting investigation in June, the company continues to evaluate potential damage claims arising from these governance issues. The divestiture proceeds are explicitly earmarked for debt reduction and capital structure improvement, providing tangible relief to investors concerned about the company's leverage profile and financial stability.
This transaction represents a calculated step in Gerresheimer's broader strategic repositioning announced earlier in 2026, designed to restore investor confidence and strengthen the company's market position within the pharmaceutical packaging industry during a period of regulatory and financial recovery.
The combined businesses delivered approximately €570m in annual revenue and operate a substantial manufacturing footprint, including 15 facilities under Primary Packaging Plastics across nine countries and Centor's US production site. The workforce across both operations totals approximately 2,400 employees. By consolidating these assets under Apax management, the transaction creates a focused player in pharmaceutical plastic packaging while enabling Gerresheimer to address its pressing balance sheet concerns.
Gerresheimer's decision to divest these operations reflects the company's efforts to recover from a challenging period marked by accounting irregularities and regulatory scrutiny. The company's financial reporting was delayed following an internal review of accounting practices, resulting in its removal from Deutsche Boerse's SDAX index and triggering audits by Germany's financial regulator, BaFin. While Gerresheimer concluded its internal accounting investigation in June, the company continues to evaluate potential damage claims arising from these governance issues. The divestiture proceeds are explicitly earmarked for debt reduction and capital structure improvement, providing tangible relief to investors concerned about the company's leverage profile and financial stability.
This transaction represents a calculated step in Gerresheimer's broader strategic repositioning announced earlier in 2026, designed to restore investor confidence and strengthen the company's market position within the pharmaceutical packaging industry during a period of regulatory and financial recovery.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.